<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>130(4)</volume><submitter>Mezquita L</submitter><pubmed_abstract>&lt;h4>Background&lt;/h4>Resistance mechanisms to combination therapy with dabrafenib plus trametinib remain poorly understood in patients with BRAF&lt;sup>V600E&lt;/sup>-mutant advanced non-small-cell lung cancer (NSCLC). We examined resistance to BRAF inhibition by single CTC sequencing in BRAF&lt;sup>V600E&lt;/sup>-mutant NSCLC.&lt;h4>Methods&lt;/h4>CTCs and cfDNA were examined in seven BRAF&lt;sup>V600E&lt;/sup>-mutant NSCLC patients at failure to treatment. Matched tumour tissue was available for four patients. Single CTCs were isolated by fluorescence-activated cell sorting following enrichment and immunofluorescence (Hoechst 33342/CD45/pan-cytokeratins) and sequenced for mutation and copy number-alteration (CNA) analyses.&lt;h4>Results&lt;/h4>BRAF&lt;sup>V600E&lt;/sup> was found in 4/4 tumour biopsies and 5/7 cfDNA samples.</pubmed_abstract><journal>British journal of cancer</journal><pagination>682-693</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10876548</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Resistance to BRAF inhibition explored through single circulating tumour cell molecular profiling in BRAF-mutant non-small-cell lung cancer.</pubmed_title><pmcid>PMC10876548</pmcid><pubmed_authors>Oulhen M</pubmed_authors><pubmed_authors>Aldea M</pubmed_authors><pubmed_authors>Honore A</pubmed_authors><pubmed_authors>Friboulet L</pubmed_authors><pubmed_authors>Mezquita L</pubmed_authors><pubmed_authors>Deloger M</pubmed_authors><pubmed_authors>Planchard D</pubmed_authors><pubmed_authors>Howarth K</pubmed_authors><pubmed_authors>Besse B</pubmed_authors><pubmed_authors>Lecluse Y</pubmed_authors><pubmed_authors>Aberlenc A</pubmed_authors><pubmed_authors>Farace F</pubmed_authors></additional><is_claimable>false</is_claimable><name>Resistance to BRAF inhibition explored through single circulating tumour cell molecular profiling in BRAF-mutant non-small-cell lung cancer.</name><description>&lt;h4>Background&lt;/h4>Resistance mechanisms to combination therapy with dabrafenib plus trametinib remain poorly understood in patients with BRAF&lt;sup>V600E&lt;/sup>-mutant advanced non-small-cell lung cancer (NSCLC). We examined resistance to BRAF inhibition by single CTC sequencing in BRAF&lt;sup>V600E&lt;/sup>-mutant NSCLC.&lt;h4>Methods&lt;/h4>CTCs and cfDNA were examined in seven BRAF&lt;sup>V600E&lt;/sup>-mutant NSCLC patients at failure to treatment. Matched tumour tissue was available for four patients. Single CTCs were isolated by fluorescence-activated cell sorting following enrichment and immunofluorescence (Hoechst 33342/CD45/pan-cytokeratins) and sequenced for mutation and copy number-alteration (CNA) analyses.&lt;h4>Results&lt;/h4>BRAF&lt;sup>V600E&lt;/sup> was found in 4/4 tumour biopsies and 5/7 cfDNA samples.</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 Mar</publication><modification>2025-04-22T11:05:49.335Z</modification><creation>2025-04-05T23:52:24.121Z</creation></dates><accession>S-EPMC10876548</accession><cross_references><pubmed>38177660</pubmed><doi>10.1038/s41416-023-02535-0</doi></cross_references></HashMap>